Edwards Lifesciences Corp Investor and Analyst TAVR & TMTT Q&A Session at TCT Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Travis Steed - Bank of America - Analyst : So Travis Steed, Bank of America. Maybe just high level, you still recently have seen the surgeon community, they say, we're doing too much TAVR in low risk patients. Is this the data? Do you think this is definitive evidence now where you can say TAVR's durable and you can start to see more referrals come in the low risk population?

Question: Marie Thibault - BTIG LLC - Analyst : Marie Thibault, BTIG. As we think about this data, how does it sort of play into potential developments with the NCD and who needs to be part of work flow? Is this data that CMS is looking at? Is this something that you make available? Just any comments probably for Bernard and Dan.

Question: Matt Miksic - Barclays Services Corp - Analyst : Thanks so much. Matt Miksic, Barclays. So just on EVOQUE and tricuspid, what are some of the most significant, and this I guess is for, Dr. Sharma and for the team, is constraints to further roll out at this point? How much is imaging a part of that challenge and imaging teams and what over the intermediate long-term can be done to kind of simplify that execution of the interventionalist in the imaging team. Thanks. Unidentified Company Representative Well, do you want to talk about your center maybe and I can talk about a little broadly.